Healio (4/23, Gramigna) reported, “Benzoate treatment appeared to improve cognitive function among women with later-phase dementia,” investigators concluded after analyzing “data of 97 patients (64% women; mean age, 75.4 years) with behavioral and psychological symptoms who were included in a randomized, double-masked, placebo-controlled trial that took place across three major medical centers in Taiwan.” Trial participants “received six weeks of treatment with 250 mg to 1,500 mg per day of sodium benzoate (n = 49) or placebo (n = 48).” The findings were published online in JAMA Network Open. (SOURCE: APA Headlines)
- ) strategy and implementation of activities aimed at increased supports for caregivers of persons with mental illness, in addition to the continued work of the Coalition and sustaining the collaboration between aging and behavioral health providers at the local level.
- Studies Support Effectiveness Of Ketamine, Esketamine For Difficult-To-Treat Depression, MDD With Suicidal Ideation, Expert Says
- In Small Study, Investigational Nondopamine Antipsychotic Show Signals It May Improve Psychosis Symptoms In Patients With Parkinson’s Disease
- Benzoate Treatment Appears To Improve Cognitive Function Among Women With Later-Stage Dementia In Small Study
- More Than One In Ten Patients Who Receive An ICD May Also Develop Anxiety Or Depression, Research Suggests